New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.

Agostino Guida Francesco PerriFranco IonnaPaolo A AsciertoAntonio M Grimaldi

Published in: Clinical case reports (2020)

Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.

Keyphrases

late onset
end stage renal disease
early onset
ejection fraction
newly diagnosed
chronic kidney disease
palliative care
prognostic factors
peritoneal dialysis
stem cells
emergency department
quality improvement
squamous cell carcinoma
adverse drug
patient reported
bone marrow